Pluristem Therapeutics Inc (PSTI)

[zzaatt]

Loxo’s first medicine, Vitrakvi, was approved by the Food and Drug Administration in November based on evidence that it can shrink tumors in 75 percent of patients whose cancer tests positive for a particular kind of genetic mutation. For 39 percent of those who respond, the tumor stays shrunk for a year or more. But this mutation, called a TRK fusion, only exists in about 3 percent of cancer patients

Eight billion dollars for the Loxo Oncology acquisition, for a drug that is effective in 3% of patients, and of whom 39% is benefitting after a year. Compare that to PAD, and you can see the possibilities IF the company can show approvable benefit for just this indication, not to mention the rest of PSTI's platform.

Looks like the biotech sector might be coming back, and that would make this year a particularly good time for convincing data from one or more of PSTI's current efforts. The possibility for a buyout at multiples of the LOXO deal is quite realistic (again, if PSTI continues with good data, and thus establishes MSCs as the revolutionary new technology we all hope for).